Clinical Trial Update: Desmopressin Response in the Young [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluating desmopressin response in young patients with primary nocturnal enuresis has completed. The sponsor is Ferring Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nocturnal Enuresis

Drugs mentioned

• Desmopressin (DDAVP) (Desmopressin)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Primary Nocturnal Enuresis | Phase 3 | Status: COMPLETED